Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Vyvanse TM

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.

Active ingredients: lisdexamfetamine

Brand name

(ARTG)

: VYVANSE lisdexamfetamine dimesilate 50mg capsule bottle

Download the Consumer Medicine Information Leaflet

Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website

What this medicine is used for

(ARTG)

Attention Deficit Hyperactivity Disorder (ADHD): VYVANSE is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Treatment should be commenced by a specialist. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before 12 years of age.,Need for comprehensive treatment programme: VYVANSE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational and social) for patients with this syndrome. Stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physicians assessment of the chronicity and severity of the patients symptoms.,Long term use: The physician who elects to use VYVANSE for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.,Binge Eating Disorder (BED): VYVANSE is indicated for the treatment of moderate to severe BED in adults when nonpharmacological treatment is unsuccessful or unavailable. Treatment should be commenced and managed by a psychiatrist.,Need for comprehensive treatment programme: VYVANSE is indicated as part of a total treatment program for BED that optimally includes other measures (nutritional, psychological, and medical) for patients with this disorder. When remedial measures including psychotherapy are insufficient, the decision to prescribe stimulant medication will depend upon the physicians assessment of the chronicity and severity of the patients symptoms.,Limitation of Use: VYVANSE is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of VYVANSE for the treatment of obesity have not been established. Prescribers should consider that serious cardiovascular events have been reported with this class of sympathomimetic drugs. The BED clinical trials were not designed to assess cardiovascular safety. While there is an accumulation of safety data with VYVANSE use in the ADHD population, this is of limited relevance regarding cardiovascular risk in the BED population. Given the higher cardiovascular risk associated with obesity, the BED population may be at a higher risk. See Sections 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Cardiovascular Disease and 4.2 DOSE AND METHOD OF ADMINISTRATION.,Long term use: For BED the initial treatment period is 12 weeks. Patients should then be observed to assess whether further treatment with VYVANSE is required. Periodic re-evaluation of the usefulness of VYVANSE for the individual patient should be undertaken. See Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials.

How to use this medicine

(ARTG)

This medicine contains one component only.

Component :

  • Capsule, hard
  • Oral
  • Hard Capsule Size 3: white opaque body and blue opaque cap, printed 'S489' and '50 mg' in black ink

Storage conditions

(ARTG)

  • Store below 25 degrees Celsius
  • Shelf lifetime is 36 Months.

Do I need a prescription ?

(ARTG)

These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.

  • 30 pack

Is this medicine subsidised ?

(PBS)

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.

Pregnant or planning a pregnancy ?

(AHT)

For the active ingredient lisdexamfetamine

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

Back to top back to top

Need more information?

These trusted information partners have more on this topic.

Top results

ADHD Medication and Treatments - ADHD Foundation Australia

In Australia, psychiatrists prescribe ADHD medication. For more details, reach out to the ADHD Foundation Australia. The PBS approved Vyvanse for adults over 18 in January 2021.

Read more on ADHD Foundation Australia website

About the shortage of Ordine (morphine) oral liquid | Therapeutic Goods Administration (TGA)

Find out about the shortage of Ordine (morphine) oral liquid.

Read more on TGA – Therapeutic Goods Administration website

About the Ozempic (semaglutide) shortage 2022 - 2024 | Therapeutic Goods Administration (TGA)

Check this page for key information and updates on the Ozempic shortage.

Read more on TGA – Therapeutic Goods Administration website

Healthdirect 24hr 7 days a week hotline

24 hour health advice you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information and advice

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Queensland Government logo Government of South Australia, health department logo Tasmanian government logo Victorian government logo Government of Western Australia, health department logo

Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and present.